Insider TradingJun 22, 2026, 05:07 PM
Crescent Biopharma Executives Adopt 10b5-1 Trading Plans
AI Summary
Crescent Biopharma, Inc. filed an amendment to its 10-Q to disclose that several key executives, including the CEO, COO, and CFO, adopted Rule 10b5-1 trading arrangements on February 25, 2026. These 'Sell-to-Cover' plans are designed to satisfy tax withholding obligations arising from the vesting of restricted and performance stock units. The amendment also includes new certifications from the principal executive and financial officers, clarifying that no financial statements were altered.
Key Highlights
- Seven Crescent Biopharma executives, including the CEO and CFO, adopted Rule 10b5-1 trading arrangements.
- The 'Sell-to-Cover' plans were adopted on February 25, 2026.
- Plans are for satisfying tax withholding obligations from vesting restricted and performance stock units.
- The arrangements cover awards under the 2025 Stock Incentive Plan, 2025 Employment Inducement Incentive Award Plan, and 2024 Equity Incentive Plan.
- No other directors or officers adopted or terminated 10b5-1 plans during Q1 2026.
- The disclosure was added via an amendment to a 10-Q, correcting an inadvertent omission.
- New certifications from the Principal Executive Officer and Principal Financial Officer were filed.
Price Impact
More from CBIO